BEAM

Beam Therapeutics Inc.

$24.19

+3.07% 2026-10-19

Healthcare

1M 3M 6M 1Y 2Y

BEAMSPY

-3.7%

-3.0%

-8.1%

-22.4%

YTD

-12.7%

-6.9%

Grades vs sector

Momentum

no data

–

Percentile within its GICS sector across the S&P 1500.

Growth

no data

–

Percentile within its GICS sector across the S&P 1500.

Value

no data

–

Percentile within its GICS sector across the S&P 1500.

Profitability

no data

–

Percentile within its GICS sector across the S&P 1500.

Revisions

no data

–

30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 3 live models right now.

Momentum Top 15

not ranked (outside this model's universe or screens)

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Blend

not in the current book

Key stats

Market cap$2.5B

P/E (trailing)–

P/E (forward)-5.1

52-week range20.23 – 38.26

Revenue growth (YoY, latest qtr)-94.2%

Dividend yield0.00%

Analyst consensusStrong Buy (13)

Mean price target$52.15 (+116%)

Valuation & fundamentals

Bottom line

No cash-flow valuation

Model read-out from the numbers below, not advice. Score +1 (DCF counts double).

•Piotroski F-score4/9

•Altman Z3.0 (grey)

▲Analyst target+116% (13 analysts)

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.

Reverse DCFfor context, not a signal

Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 2.20 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $-4.74 vs trailing $-0.68. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin

–

Operating margin

-242.3%

FCF margin

-238.9%

Net margin

-55.4%

Return on equity

-8.1%

Return on invested capital

-2021.5%

Net debt / EBITDA

–

Current ratio

14.6×

Interest cover

–

Cash conversion (OCF/NI)

–

Piotroski F-score 4/9 · last two fiscal years

✗ Positive net income✗ Positive operating cash flow✓ Return on assets improved✗ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score 3.0 (grey zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$52

+116%

Analysts

Strong Buy

Range

$26–$80

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$139.7M	$-80.0M	$-360.0M
2024	$63.5M	$-376.7M	$-356.2M
2023	$377.7M	$-132.5M	$-182.9M
2022	$60.9M	$-289.1M	$-26.4M
2021	$51.8M	$-370.6M	$-113.1M
2020	$24.0K	$-194.6M	$-112.1M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +31.9%.

Earnings

Next report: 2026-11-03 · before open · EPS est -1.17

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-04	-1.13	-1.18	-4.8%
2026-05-07	-1.01	-0.91	+10.1%
2026-02-24	-1.12	2.33	+309.0%
2025-11-04	-1.01	-1.10	-8.9%
2025-08-05	-1.09	-1.00	+8.4%
2025-05-06	-1.17	-1.24	-5.9%
2025-02-25	-1.22	-1.09	+10.3%
2024-11-05	-1.16	-1.17	-0.7%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$490.0K	-94.2%
2026-03-31	$31.7M	–
2025-12-31	$114.1M	–
2025-09-30	$9.7M	–
2025-06-30	$8.5M	–

Analyst actions

HC Wainwright & Co.

2026-10-15 · reit

Buy → Buy
PT $80

Wedbush

2026-10-14 · reit

Outperform → Outperform
PT $65

Wedbush

2026-09-09 · reit

Outperform → Outperform
PT $65

HC Wainwright & Co.

2026-08-25 · reit

Buy → Buy
PT $80

B of A Securities

2026-07-08 · reit

Buy → Buy
PT $47

HC Wainwright & Co.

2026-07-07 · reit

Buy → Buy
PT $80

Insider trades

Evans John M.

Director, CEO · 2026-10-16

SELL
$599.6K

Evans John M.

Director, CEO · 2026-10-15

SELL
$589.1K

Cavanagh Bethany J

SVP, Finance and Treasurer · 2026-10-01

SELL
$4.6K

Simon Amy

Chief Medical Officer · 2026-07-27

SELL
$429.0K

None

None · None

SELL
–

News

3M announces collaboration with GSEO to advance Expanded Beam Optical manufacturing and development

PR Newswire · 13h ago

Empyrean Medical Systems Submits its Bespoke Vektra™ Beam Sculpting Radiation Therapy System to FDA

PR Newswire · 19h ago

Beam Therapeutics Insider Sold Shares Worth $1,188,745, According to a Recent SEC Filing

MT Newswires · Oct 19

Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?

Motley Fool · Oct 17

Beam Global's Pending Drone Company Acquisition ScoutDI Wins Milestone Order from Nuclear Sector Customer

GlobeNewswire · Oct 15

Global Molecular Beam Epitaxy (MBE) Equipment Market Size, Share, Trends, and Forecast, 2026-2031 | Quantum Computing, Next-Gen Chips, and Cluster Automation Fuel 7%-8% CAGR

GlobeNewswire · Oct 14

UPDATE: Beam Global Announces Preliminary Third Quarter 2026 Revenue Growth of 8% Year Over Year, Advancing Strong Core Business for Strategic Expansion into Drone Technology

GlobeNewswire · Oct 13

Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress

GlobeNewswire · Oct 13

Stats refreshed 2026-10-19 19:03:13 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Coteau Systematic StrategiesSystematic equity research and model portfolios.
Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.

What is Coteau?Disclaimer Terms Privacy Data status